Cytolytix Patent Granted

AI SummaryClose X

ValiRx Plc's subsidiary, Cytolytix Limited, has been granted a European patent for its nanoparticle anti-cancer peptide technology, strengthening its intellectual property portfolio and potential for investment and licensing. Additionally, Cytolytix has filed a new patent application for a second-generation delivery platform utilizing liposomal formulations of oncolytic peptides, supported by data showing induction of immunogenic cell death in triple-negative breast cancer cells, which could lead to enhanced clinical responses. The company is actively pursuing partnerships with pharmaceutical companies and exploring non-dilutive funding options.

Disclaimer*

Companies

Valirx (VAL)
UK 100

Latest directors dealings